Changes in Cardiopulmonary Variables and Platelet Count During Anesthesia for Total Hip Replacement in Dogs

Changes in cardiopulmonary function and platelet count were determined in 22 dogs of various breeds that underwent total hip replacement with cemented femoral prostheses. In 11 dogs (group I) polymethylmethacrylate (PMMA) was inserted without venting the reamed and lavaged femoral canal. In a second group of 11 dogs (group II) a urethral catheter (ID: approximately 2.7 mm) was placed into the medullary cavity before the insertion of PMMA. The application of PMMA resulted in a decrease in end-tidal carbon dioxide tension (PETco₂) until 5 minutes after insertion of bone cement. Increases in arterial to end-tidal pCO₂ gradient [P(a-ET)co₂] and physiological dead space (V_D/V_T) were recorded between 2 minutes before and 5 minutes after insertion of PMMA in 12 dogs. A significant decrease in platelet count occurred in both groups of dogs. Decreases in arterial pO₂ (Pao₂), arterial/alveolar oxygen tension ratio (Pao₂/PAo₂), and percent O₂ saturation of hemoglobin in arterial blood (Sao₂) were not statistically significant. No significant differences could be detected between data obtained from both groups of dogs. An increase in femoral intramedullary pressure caused by the insertion of PMMA and subsequent pulmonary microembolism by medullary contents has been considered the most likely cause for changes in pulmonary function. The lack of statistically significant differences in cardiopulmonary variables and platelet count between the two groups of dogs could have been related to inefficient pressure reduction by the method used.     

Cardiorespiratory Effects of Four Opioid-Tranquilizer Combinations in Dogs

The cardiorespiratory effects of four opioid-tranquilizer combinations were evaluated in six dogs. The four combinations were administered to each dog in a randomized order. Buprenorphine (BUP; 0.01 mg/kg IV) or oxymorphone (OXY; 0.1 mg/kg IV) was followed in 10.4 ± 1.3 minutes by midazolam (MID; 0.3 mg/kg IV) or acepromazine (ACE; 0.05 mg/kg IV). Nalbuphine (0.16 mg/kg IV) was administered 94.1 ± 2.3 minutes after the tranquilizer was given. Heart rate (HR) and mean arterial blood pressure (MAP) decreased significantly ( P < .05) after each combination. MAP was significantly lower with combinations using ACE. Most dogs panted after opioid administration; this was associated with increased minute volume (V_M) and decreased tidal volume (V_T). After administration of the tranquilizer, mean breathing rate and V_M index (V_MI) were significantly lower with ACE combinations. There were no significant changes in pH and blood gas variables after BUP-ACE. The other three combinations were associated with significant ( P < .05) decreases in pH and increases in Paco₂. Mean Pao₂ decreased significantly ( P < .05) with OXY combinations but not BUP combinations. Dysrhythmias (atrial or ventricular escape complexes) were seen with each combination. HR increased significantly ( P < .05) after nalbuphine in dogs receiving OXY, but not BUP. Dogs receiving OXY became more alert after nalbuphine on six of 12 occasions, whereas dogs receiving BUP became less alert on six of 12 occasions. OXY-ACE provided the most chemical restraint/sedation and BUP-MID provided the least.     

The Influence of Body Position on the Blood Gas and Acid-base Status of Halothane-anesithetized Sheep

Eleven adult sheep were divided into three groups. Baseline arterial blood samples were taken with the sheep standing and breathing room air. They were then anesthetized and placed in right (group one), left (group two), or dorsal (group three) recumbency. Arterial blood samples were taken at 30, 60, 90, and 120 minute intervals during anesthesia, and 15 minutes after the discontinuation of halothane in oxygen.
Anesthetic induction resulted in an increase in arterial oxygen (Pao₂) and carbon dioxide (Paco₂) tensions and a decrease in arterial pH (pHa) and base excess (BE). During anesthetic maintenance, no positional effects were noted, and pHa and BE increased in all groups. With the termination of anesthesia and the animals breathing room air, pHa increased, and Pao₂ and Paco, decreased; BE was elevated in group two when compared to group three. Only BE had returned to control values 15 minutes after halothane was discontinued.     

Butorphanol Tartrate for Partial Reversal of Oxymorphone-Induced Postoperative Respiratory Depression in the Dog

A randomized, blinded, crossover study was designed to evaluate the respiratory, cardiovascular, and behavioral effects of butorphanol given postoperatively to oxymorphone-premedicated and surgically stimulated dogs. Nine healthy adult dogs were premedicated intramuscularly with atropine (0.04 mg/kg), acepromazine (0.10 mg/kg), and oxymorphone (0.2 mg/kg). Anesthesia was induced with thiamylal (12 mg/kg) and maintained with halothane in oxygen. According to the protocol of a concurrent study, all dogs had percutaneous endoscopic gastrostomy (PEG) feeding tubes placed during the first anesthetic episode and removed during the second anesthetic episode. All dogs received postoperatively either butorphanol tartrate (0.2 mg/kg) or an isovol-umetric dose of saline placebo, both given intravenously. Respiratory rate (RR), tidal volume (TV), minute ventilation (MV), end-tidal CO₂ concentration (ET_CO2). heart rate (HR), and indirect diastolic (DP), systolic (SP) and mean arterial (MAP) blood pressures were measured at times 0, 2, 5, 10, 20, 40, 80, and 120 minutes after injection. The time from injection of the test drug until extubation was recorded. RR, MV, HR, and DP were significantly ( P < .05) increased, while ET_co2 was significantly decreased, for a minimum of 30 minutes in butorphanol-treated dogs compared with saline controls. TV, SP, and MAP were transiently (≤15 minutes) increased in butorphanol-treated dogs compared with saline controls. There was no significant difference between the times to extubation in the butorphanol-treated dogs versus the saline control dogs.     

Frequency of pulmonary mineralization and hypoxemia in 21 dogs with pituitary-dependent hyperadrenocorticism

The purpose of this study was to determine the frequency of hypoxemia and pulmonary mineralization using ^99mTc-methylene diphosphonate (^99mTc-MDP) in dogs with pituitary-dependent hyperadrenocorticism (PDH). Twenty-one dogs with PDH were pro-spectively evaluated using thoracic radiography, arterial blood gas analysis, and bone phase and pulmonary perfusion scintigraphy (using ^99mTc-macro-aggregated albumin [^99mTc-MAA]). The radiographs and bone and perfusion studies were evaluated subjectively. An averaged quantitative count density ratio was calculated between the thorax and cranial thoraco-lumbar vertebrae from lateral thoracic ^99mTc-MDP images. Thoracic: vertebral ratios were calculated using ^99mTc-MDP studies from 21 control dogs. The thoracic: vertebral ratios were compared between the 2 groups (PDH and control). The mean age (±SD) of the 21 PDH dogs was 10.2 (±3) years, whereas the mean age of the control group was 9.8 (±3) years. Seven of the 21 dogs with PDH were hypoxemic (denned as an arterial partial pressure of oxygen [PaO₂] <80 mm Hg) with an average PaO₂ (±SD) of 62 (±15) mm Hg. Of the 7 hypoxemic dogs, 2 were found to have pulmonary mineralization based on bone scintigraphic images. Pulmonary perfusion abnormalities were not identified using ^99mTc-MAA in any of the 21 PDH dogs. Six PDH dogs had an abnormal interstitial pulmonary pattern and 5 of these dogs were hypoxemic. The average quantitative thoracic: vertebral ratio was not significantly different between the PDH and control dogs (0.5 ± 0.4 versus 0.4 ± 0.1, P = .16). Causes of hypoxemia other than pulmonary thromboembolism should be considered in dogs with PDH. Pulmonary mineralization may contribute to hypoxemia in dogs with PDH.     

PULMONARY VENOUS FLOW CHARACTERISTICS AS ASSESSED BY TRANSTHORACIC PULSED DOPPLER ECHOCARDIOGRAPHY IN NORMAL DOGS

Transthoracic Doppler echocardiography was used to evaluate the technique of measuring and normal patterns of pulmonary venous flow in fourteen normal dogs. Polyphasic pulmonary venous flow profiles were obtained in all dogs, consisting of one (S) or two (S_E and S_L) systolic forward flow waves, one early diastolic forward flow wave (D), one reverse flow wave (R) related to atrial contraction, and one reverse flow wave (R₂) observed after cessation of systolic flow. Pulmonary venous flow was laminar in 9 dogs (65%). Maximal flow velocity during systole (0.39 ± 0.14 m/sec) was significantly lower (P < 0.01) than in early diastole (0.56 ± 0.14 m/sec). During late diastole peak flow velocity was 0.20 ± 0.08 m/sec and maximum R₂ velocity was 0.17 ± 0.05 m/sec. Duration of mitral A-wave was significantly greater (P < 0.05) than R-wave duration in all dogs (0.075 ± 0.10 vs 0.058 ± 0.012 sec). These results can be used for comparison with patterns found in disease states.     

High-Frequency Jet Ventilation in Anesthetized, Paralyzed Dogs and Cats Via Transtracheal and and Endotracheal Tube Routes

The ability of the SAV 6 high-frequency jet ventilator to effectively ventilate three anesthetized, paralyzed cats (3.2–4.2 kg), two small dogs (7.2 and 10.0 kg), six medium-sized dogs (20.5–25.0 kg), and three large dogs (36.0–43.0 kg) via a 14-gauge (dogs) or a 16-gauge (cats) catheter placed percutaneously into the trachea via the cricothyroid membrane or into a preplaced endotracheal tube was evaluated. The lowest driving pressure within the range of 0.25 to 2.0 kg/cm² (1 kg/cm²= 14.2 psi) and the highest cycle rate within the range of 60 to 240 per minute that would generate a PaCO₂ of 30 ± 3 mm Hg were determined.
All animals could be ventilated to a PaC0₂ of 30 ± 3 mm Hg by the endotracheal tube and transtracheal route, except the largest dogs, which couid be ventilated to an average PaC0₂ of 36 mm Hg by the transtracheal route. The transtracheal route consistently required higher driving pressures and lower cycle rates than did the endotracheal tube route. Cats could be ventilated with a driving pressure of 0.25 kg/cm²; small dogs could be ventilated with 0.5 to 1.0 kg/cm₂; medium-sized dogs with 1.0 to 1.5 kg/cm²; and large dogs with 1.5 to 2.0 kg/cm².
The SAV 6 high-frequency jet ventilator can effectively ventilate cats and dogs (7.2–43.0 kg) via a transtracheal catheter and an endotracheal tube.     

Sedative effects of propofol in horses

Objective  We hypothesized that propofol can produce rapidly-reversible, dose-dependent standing sedation in horses.
Study design  Prospective randomized, blinded, experimental trial.
Animals  Twelve healthy horses aged 12 ± 6 years (mean ± SD), weighing 565 ± 20 kg, and with an equal distribution of mares and geldings.
Methods  Propofol was administered as an intravenous bolus at one of three randomized doses (0.20, 0.35 and 0.50 mg kg⁻¹). Cardiovascular and behavioral measurements were made by a single investigator, who was blinded to treatment dose, at 3 minute intervals until subjective behavior scores returned to pre-sedation baseline values. Continuous data were analyzed over time using repeated-measures anova and noncontinuous data were analyzed using Friedman tests.
Results  There were no significant propofol dose or temporal effects on heart rate, respiratory rate, vertical head height, or jugular venous blood gases (pH_v, P_vO₂, P_vCO₂). The 0.35 mg kg⁻¹ dose caused mild sedation lasting up to 6 minutes. The 0.50 mg kg⁻¹ dose increased sedation depth and duration, but with increased ataxia and apparent muscle weakness.
Conclusions and clinical relevance  Intravenous 0.35 mg kg⁻¹ propofol provided brief, mild sedation in horses. Caution is warranted at higher doses due to increased risk of ataxia.     

Pharmacokinetics of sulphadimidine in normal and febrile dogs

Pharmacokinetic parameters which describe the distribution and elimination of sulphadimidine were determined in normal dogs and dogs in which fever was produced by an intravenous injection of escherichia and staphylococcal species of bacteria. Sulphadimidine was injected as a single intravenous bolus at the dose of 100 mg/kg and the kinetics of the drug were described in terms of the bi-exponential expression: C_p = Ae ^{-α t} + Be ^{-β t} . The distribution half-times of the drug were 1.52 h in the normal and 0.81 h in the febrile dogs. The drug distribution was significantly more rapid ( P < 0.05) in febrile than in normal dogs. Average ± SD values for the half-lives of the drug were 16.2 ± 5.7 h in normal and 16.7 ± 4.7 h in the febrile dogs. The apparent volume of distribution ( V ' _d (area)) was 628 ± 251 ml/kg in the normal dogs, and was not statistically different from 495 ± 144 ml/kg in the febrile dogs. The volume of the central compartment ( V ' _c ) was 445 ± 55 ml/kg in normal dogs and this was significantly higher ( P < 0.01) than the V ' _c of 246 ± 72 ml/kg in the febrile dogs. The body clearance was 22.4 ± 4.8 and 20.2 ± 3.6 ml/hour. kg in the normal and febrile dogs, respectively. The investigation revealed that the dosage regimen of sulphadimidine did not differ significantly between normal and febrile dogs.     

GASTRIC EMPTYING OF SOLID RADIOPAQUE MARKERS IN HEALTHY DOGS

The gastric emptying of 1.5 mm diameter (small) and 5.0 mm diameter (large) radiopaque markers (BIPS) was assessed in 20 dogs. The markers were fed to the dogs in a test meal and abdominal radiographs were made hourly thereafter. Studies were repeated three times in each dog. The variation between two veterinarians interpreting the radiographs was low. The sex, age and day of the study did not have a significant effect on the lag phase or the time taken to empty 25%, 50% and 75% of the markers (T₂₅, T₅₀ and T₇₅ respectively). There was a weak but significant positive correlation between the body weight and T₅₀. There was no significant difference in gastric emptying parameters between the large and small markers.
The mean gastric emptying versus time curve of the small markers on day one was chosen to represent the reference curve for healthy dogs. The lag phase of the small markers on day one was 2.45 ± 2.04 hours, the T₂₅ was 4.85 ± 2.15 hours, the T₅₀ was 6.05 ± 2.99 hours and the T₇₅ was 8.32 ± 2.72 hours (mean ± SD).     

PRACTICALITY, USEFULNESS, AND LIMITS OF END-TIDAL CARBON DIOXIDE MONITORING IN CRITICAL SMALL ANIMAL PATIENTS

End-tidal monitors for measuring carbon dioxide (CO₂) have become widely available for clinical use in the last two decades. This non-invasive technology has been previously evaluated in anesthetized veterinary patients, but its accuracy has not been assessed in critical patients. We investigated the usefulness and limits of end-tidal CO₂ monitoring in two populations of critical small animal patients: spontaneously breathing dogs and mechanically ventilated patients with healthy and damaged lungs. In analyzing samples from 43 spontaneously breathing dogs and 34 ventilated patients (28 dogs and six cats), the end-tidal CO₂ was generally lower than pCO₂. The predictive value for hypoventilation was excellent in both populations (100%). The linear correlation of the end-tidal CO₂ and arterial pCO₂ in non-panting dogs with healthy lungs was 0.84 (p<0.0001), and the 95% confidence interval (CI) of the difference was ± 3.2 mm Hg. However, the measures were uncorrelated in panting dogs (r=0.37, p=0.27), and the 95% CI was ± 13.37 mm Hg. Furthermore, where multiple samples could be obtained in individual patients, the r values and differences of end-tidal compared to arterial pCO₂ varied unpredictably. These variations did not appear to be predicted by patient factors such as lung disease. We conclude that the end-tidal CO₂ monitor is clinically useful for detecting hypoventilation and monitoring apnea, but it should be supplemented with arterial pCO₂ determinations if it is important to obtain accurate pCO₂ measures.     

Blood oxygen and carbon dioxide tensions in normal dogs and in dogs with respiratory failure

Arterial blood samples were obtained from thirty normal conscious dogs breathing air. The mean values and standard deviations recorded were PaO₂ 101.3±5.6 mmHg, PaCO₂ 34.0±3.9 mmHg, oxygen saturation 93.8 ±1.2%, oxygen content 19.3 ± 1.8 ml/100 ml. Ten dogs with respiratory problems were also examined and of these animals seven had lower than normal oxygen tensions while three had carbon dioxide levels higher than those found in healthy dogs. It was concluded that, in severe respiratory disease, measurement of arterial oxygen tension gives a useful assessment of respiratory failure in dogs.     

Cardiopulmonary and Analgesic Effects of Epidural Lidocaine, Alfentanil, and Xylazine in Pigs Anesthetized With Isoflurane

To determine cardiopulmonary and analgesic effects of lidocaine, alfentanil, and xylazine in pigs anesthetized with isoflurane, 18 healthy Landrace-Large White pigs were studied (six for each drug). General anesthesia was induced with isoflurane in O₂ and maintained with 1% to 1.2% end-tidal ISO, ensuring presence of a pain response before epidural drug administration. Heart rate (HR), arterial blood pressures (AP), cardiac output (CO), pulmonary arterial pressure, pulmonary capillary wedge pressure (PCWP), central venous pressure, respiratory rate (RR), tidal volume (TV), minute volume (MV), arterial blood gas data, core temperature (CT), and analgesic effects (by pricking the lumbar area and the abdominal wall) were determined at various times (2, 5, 15, 30, 45, 60, and 90 minutes) after epidural administration of lidocaine (5 μg/kg), alfentanil (5 μg/kg), or xylazine (0.2 mg/kg), all diluted in NaCl 0.9% to 0.5 mL/kg. Statistical analysis included two-way analysis of variance for repeated measures and the least significant difference test for determining differences among means. A probability level of P <.05 was used. The following results were statistically significant decreases in systolic AP, HR, TV, RR, MV, CT, pH, PaO₂, and TCO₂ and increases in PCWP, PaCO₂, and HCO₃ after LID. After ALF, only CT and HCO₃ decreased. Core temperature and TV decreased after XYL. Lidocaine provided 45 to 60 minutes of analgesia. Alfentanil had no analgesic effects, and xylazine provided 90 minutes of analgesia. The authors conclude that xylazine, when injected epidurally, provides suitable analgesia in isoflurane-anesthetized pigs.     

Anesthesia in Sheep With Propofol or With Xylazine-Ketamine Followed by Halothane

Objective- This study evaluates the clinical usefulness and anesthetic effect of propofol, and compares these effects with those of xylazine-ketamine-halothane anesthesia in sheep.
Study Design- Prospective, randomized, clinical trial. Animals or Sample Population- Fourteen healthy adult male sheep.
Methods- Sheep were randomly assigned to two different drug regimens: (1) Bolus injection of propofol (3 mg/kg, intravenously [IV]) followed by continuous intravenous infusion and (2) xylazine (0.11 mg/kg, IV) and ketamine (2.2 mg/kg, IV) for induction followed by halothane anesthesia. Heart rate, respiratory rate, and arterial blood pressures were monitored during anesthesia. Venous blood samples were collected for blood gas analysis. Quality of induction and recovery were also recorded.
Results- The average dose of propofol used to induce and maintain anesthesia was 6.63 ±2.06 mg/kg and 29.3 ±11.7 mg/kg/hr (0.49 ±0.20 mg/kg/min), respectively. The duration of propofol anesthesia was 45.3 ±13.2 minutes and recovery to standing occurred in 14.7 ±5.7 minutes. Sheep receiving xylazine-ketamine-halothane were anesthetized for 35.9 ±4.0 minutes and recovery to standing occurred within 28.5 ±7.5 minutes. Sheep anesthetized with propofol had a significantly higher heart rate, diastolic blood pressure and Pvo₂, and a lower Pvco₂ at 30 minutes and lower BE at 15 and 30 minutes than sheep anesthetized with xylazine-ketamine-halothane.
Conclusions- Propofol anesthesia was characterized by a smooth induction, effective surgical anesthesia and rapid recovery which was comparable to anesthesia with xylazine-ketamine-halothane.
Clinical Relevance- Propofol may be indicated in situations when it is desirable to maintain anesthesia with an intravenous infusion followed by a rapid recovery in healthy sheep.     

Pharmacokinetics of imidocarb in normal dogs and goats

The pharmacokinetics of imidocarb were studied in seven mongrel dogs and eight crossbred goats. An intravenous bolus dose (4 mg/kg) of 12% imidocarb dipropionate solution wasinjected into the cephalic vein in dogs and the jugular vein in goats. The plasma concentration of imidocarb was measured by spectro-photometry. The experimental data were analysed using a two-compartment open model. The apparent volume of the central compartment was significantly higher ( P <0.01) in dogs than in goats. The significantly larger ( P <0.05) apparent specific volume of distribution in goats than in dogs may be attributed to passive diffusion followed by ion trapping of the drug in rumen fluid. Neither the half-life nor body clearance differed significantly between dogs ( t _1/2, 207 ± 45 min; Cl_B , 1.47 ± 0.38 ml/min kg) and goats ( t _1/2, 251 ± 94 min; Cl_B , 1.62 ± 0.50 ml/min kg). While almost 80% of the dose had been eliminated at 8 h in. both species, the high ratio of the imidocarb level in the peripheral-to-central compartment in goats suggests that a prolonged period may be required for complete elimination of the drug.     

THE USE OF99mTc RADIOAEROSOL VENTILATION AND MACROAGGREGATED ALBUMIN PERFUSION IMAGING FOR THE DETECTION OF PULMONARY EMBOLI IN THE DOG

This study was undertaken to design protocol for use of radioaerosol of technetium-99m-labeled diethylenetriaminepentacetic acid (^99mTc-DTPA) for ventilation imaging as clinical tool in the dog and to evaluate imaging characteristics in both normal dogs and dogs with simulated pulmonary embolism. Clearance of the 99mTc-DTPA radioaerosol from the lung was also evaluated. Six normal dogs were used in two phases: (1) as their own controls and (2) during pulmonary artery occlusion using Swan-Ganz catheter. Radioaerosol ventilation images were obtained and rate of clearance from normal and occluded lungs determined. Perfusion studies using technetium-99m-macroaggregated albumin (^99mTc-MAA) immediately followed. Clearance half-times (T_1/2) were found to be significantly increased (p < 0.05) in acutely occluded lungs; however, the small magnitude of this change was visually difficult to detect on the ventilation images. Good quality initial ventilation and perfusion images were obtained and provided ready evaluation of ventilation (V), perfusion (Q), and induced V/Q mismatches. A clinical case of pulmonary thromboembolic disease was also evaluated with diagnostic result, indicating that this method of V/Q scintigraphy can provide useful information in those clinical cases in which pulmonary thromboembolism is suspected.     

Comparative study on the sedative effects of morphine, methadone, butorphanol or tramadol, in combination with acepromazine, in dogs

Objective  To compare the effects of morphine (MOR), methadone (MET), butorphanol (BUT) and tramadol (TRA), in combination with acepromazine, on sedation, cardiorespiratory variables, body temperature and incidence of emesis in dogs.
Study design  Prospective randomized, blinded, experimental trial.
Animals  Six adult mixed-breed male dogs weighing 12.0 ± 4.3 kg.
Methods  Dogs received intravenous administration (IV) of acepromazine (0.05 mg kg⁻¹) and 15 minutes later, one of four opioids was randomly administered IV in a cross-over design, with at least 1-week intervals. Dogs then received MOR 0.5 mg kg⁻¹; MET 0.5 mg kg⁻¹; BUT 0.15 mg kg⁻¹; or TRA 2.0 mg kg⁻¹. Indirect systolic arterial pressure (SAP), heart rate (HR), respiratory rate ( f _R), rectal temperature, pedal withdrawal reflex and sedation were evaluated at regular intervals for 90 minutes.
Results  Acepromazine administration decreased SAP, HR and temperature and produced mild sedation. All opioids further decreased temperature and MOR, BUT and TRA were associated with further decreases in HR. Tramadol decreased SAP whereas BUT decreased f _R compared with values before opioid administration. Retching was observed in five of six dogs and vomiting occurred in one dog in MOR, but not in any dog in the remaining treatments. Sedation scores were greater in MET followed by MOR and BUT. Tramadol was associated with minor changes in sedation produced by acepromazine alone.
Conclusions and clinical relevance  When used with acepromazine, MET appears to provide better sedation than MOR, BUT and TRA. If vomiting is to be avoided, MET, BUT and TRA may be better options than MOR.     

SCINTIGRAPHIC EVALUATION OF FOUR DOGS WITH PROTEIN-LOSING ENTEROPATHY USING 111INDIUM-INDIUM-LABELED TRANSFERRIN

The purpose of this sutdy was to determine the clinical utility of ¹¹¹ In-labeled transferrin ( 111 In-TF) scintigraphy for evaluating dogs suspected of having protein-losing enteropathies. Four dogs were injected intravenoulsy with autologous ¹¹¹In-TF after 30 min incubation (at 37°C) of 18.5 MBq (0.5mCi) ¹¹¹In CI₃ with one ml of autologous plasma, Serial right lateral, left lateral and dorsal images were obtained 2, 4, and 24 hours post ¹¹¹ In-TF administration, Images were subjectively evaluated for the presence or absence of ¹¹¹ within the gastrointestinal tract. The results of total protein, albumin and globulin legels and results form gastrointestinal tract. the results of total protein, albumin and globulin levels and results from gastrointestinal biopsies were recorded. In one dog, a follow-up scientigraphic study was done six months after initial evaluation and initiation of treatment for plasmocytic-lymphocytic enteritis. Gastrointestinal activity was noted by two hours in two dogs, while all four dogs had gastrointestinal activity on the 24 hour images. The mean (±std dev) plasma protein, albumin and globulin levels were 3.5 (±0.9), 1.7 (±1) and 1.8 (±0.3) respectively at the time of initial presentation. In the one dog that was evaluated after therapy, faint visualization of radioactivity within the colon was noted on the 24 hour image. Based on this study, ¹¹¹In-TF appears to be a viable scientigraphic method for evaluating dogs with suspected dogs withfd suspected protein-losing enteropathies, Potential limitations of tjis radiopharmaceutical include cost and prolonged isolation of the animal prior to release to the client due to the long physical half-life (T_½= 2.82 days).     

A Simple Apparatus for Frequent Measurement of Gastrointestinal Intraluminal PCO2

The accuracy and precision of an end-tidal infrared CO₂ monitor and customized capnography tubing system designed to measure gastrointestinal intraluminal CO₂ partial pressure (P_iCO₂) were tested in vitro. Samples were taken from the customized capnography tubing placed in either 5% or 10% CO₂ gas at discrete intervals ranging from one minute to twelve minutes. For a given time interval, the tubing PCO₂ measurement was a constant fraction of the actual PCO₂ (all standard errors < 0.02). For increasing time intervals, the ratio of the tubing PCO₂ to actual PCO₂ increased logarithmically. In the 5% and 10% CO₂, the regression coefficients were 0.89 and 0.85 for 8 French tubing and 0.99 and 0.91 for 6 French tubing. Beacuase of its accuracy and precision, this system may provide automated gastrointestinal CO₂ partial pressure monitoring at short intervals (e.g. 5 minutes), facilitating testing of the role of gastrointestinal P_iCO₂ information in treatment algorithms. (Vet Emerg & Crit Care, 1998; 8: 109–116)     

Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics

Intravenous (IV) levetiracetam (LEV) is available for humans for bridge therapy when the oral route is unavailable. We investigated the safety and pharmacokinetics of LEV administered intramuscularly (IM), IV, and orally to dogs.
Six Hound dogs received 19.5–22.6 mg/kg of LEV IM, IV and orally with a wash-out period in between. All dogs received 500 mg LEV orally and 5 mL of 100 mg/mL LEV IM. Three dogs received 500 mg of LEV IV and three dogs received 250 mg LEV IV with 250 mg given perivascularly to approximate extravasation. Safety was assessed using a pain scale at time of IM administration and histopathological examination 24 h to 5 days after injection.
Intravenous LEV half-life was 180 ± 18 min. Bioavailability of IM LEV was 100%. Mean time to T_max after IM was 40 ± 16 min. The mean C_max IM was 30.3 ± 3 μg/mL compared to the C₀ of 37 ± 5 μg/mL for IV. Mean inflammation score (0–4 scale) for IM LEV was 0.28 and for saline 0.62. Extravasation did not cause tissue damage.
Parenteral LEV is well tolerated and appears safe following IM and IV injections in dogs. Parenteral LEV should be evaluated for use in dogs with epilepsy.